Evidence map›Paper›PMID 41084760›Full record

ArticleFuture oncology (London, England)2025

User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol.

T W Lycan, S N Price, K Mileham, E Stoen, J Ruiz, J A Ohar, Dustin Norton, A L Koch, W J Petty, S A Birken

Abstract readClinical Trial Protocol
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

T W LycanDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
S N PriceDepartment of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
K MilehamDepartment of Internal Medicine, Wake Forest University School of Medicine, Charlotte, NC, USA.
E StoenDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
J RuizDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
J A OharDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Dustin NortonDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
A L KochDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
W J PettyDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
S A BirkenDepartment of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
CTSA UM1 Program at Wake ForestUM1TR004929 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jamy D Ard, KRISTIE L FOLEY · 2024 to 2026
$11.9M
Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patientsR01CA262041 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Jennifer Lynne Huberty, Ruben A. Mesa · 2022 to 2026
$2.8M
CTSA K12 Program at Wake ForestK12TR004931 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicholette D. Allred · 2024 to 2026
$2.3M
Refining Cognitive Behavioral Therapy for Insomnia in Lung Cancer Survivors: Enhancing Feasibility, Acceptability, and Symptom ManagementK99CA297014 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Sarah Newmeyer Price · 2025 to 2026
$225k
NCATS NIH HHS K12 TR004931NCATS NIH HHS UM1 TR004929NCI NIH HHS K99 CA297014NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA262041
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is the most common comorbidity among patients being treated for any type of cancer with an immune checkpoint inhibitor in the medical oncology clinic. There is a critical need to measure the treatment burden of COPD and design a scalable intervention to optimize its care. Our primary aim is to determine the ideal design of a care pathway to optimize COPD in community oncology clinics. This mixed-methods study will collect data to quantify and understand the disease burdens, components of care, and barriers in the medical oncology clinic. As per user-centered design methodology, participants at design team workshops will then integrate these data into a COPD care pathway. This study will provide critical data on the impact of COPD upon patients with cancer and identify how its care can be optimized in the medical oncology clinic. These results will directly inform a novel care pathway that will be designed for scalability in the community setting. Future studies will test this pathway versus usual care in a cluster randomized controlled trial across a network of oncology clinics.

Indexed as

Critical PathwaysNeoplasmsPulmonary Disease, Chronic ObstructiveHumansImmune Checkpoint InhibitorsImmune Checkpoint Inhibitorscare pathwayChronic obstructive pulmonary disease (COPD)comorbidityimmunotherapyimplementation sciencelungoutcomes researchsupportive care

Identifiers

PMID41084760
PMCPMC12536786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.